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ABSTRACT
Background. High sensitive troponin I 
(hsTnI) and high sensitive troponin T 
(hsTnT) are markers of cardiac dam-
age. Cardiomyocyte necrosis increases its 
blood levels. It is known that dialysis is 
cardiotoxic and that results in lack of con-
tractility of certain myocardial segments. 
This mechanism is primarily due to hypo 
perfusion of the myocardium during di-
alysis. The dialysis itself increases cardio-
vascular (CV) risk in patients by many dif-
ferent mechanisms. It has been proven that 
the incidence of heart failure is much more 
frequent in patients on hemodialysis than 
in healthy population.
The aim of this pilot study was to investi-
gate the presence of troponin T molecules 
and troponin I in dialysate and compare 
their concentrations.
Materials and Methods. The study includ-
ed 5 anuric patients (4M) on hemodialysis. 
The dialysate samples were sampled for 
each patient three times during a dialysis 
cycle. The first sample was taken after thir-
ty minutes, the second sample was taken 
in the middle of dialysis (120 minutes) and 
the third sample was taken thirty minutes 
before the end of dialysis. The value of hsT-
nI was measured using a high-sensitivity 
test on the Immuno-enzymatic analyzer 
Abbott Architest i1000SR. According to 
CLSI EP15-A2 protocol verification of 
hsTnT chemiluminescent micro-particle 
immunoassay on the analytical platform 
Roche cobas e411 was performed.
Results. Altogether 15 samples (three for 
each patient) were processed. hsTnT was 
detected in all 15 samples (13.42 ± 1.18 
ng / L), while hsTnI was detected in only 8 
samples (0.14 ± 0.16 ng / L). To test the dif-
ference in detectability between hsTnT and 
hsTnI, chi square test was used and the dif-
ference was statistically significant (Yates 
chi-square 6.708, p = 0.009).
Conclusion. The presence of troponin 
molecules in dialysate was determined for 
the first time in scientific literature. This 
study has confirmed that TnT is present in 
all dialysate samples and that its concen-
tration is stable in dialysate. TnI concentra-
tions were detectable in significantly lower 
concentrations.
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INTRODUCTION
Cardiac - specific troponins are troponin 
T (TnT) and troponin I (TnI), as different 
genetic variants of troponins exist. Since 
a morphologically different form of tro-
ponin is expressed in skeletal muscle cells, 
these two types of troponin are used as a 
specific marker of cardiac damage. In situ-
ations where cardiac necrosis occurs, they 
increase their blood concentrations. The 
most common conditions that lead to el-
evation of the troponin level in the blood 
are myocardial infarction, pulmonary em-
bolism and toxic heart damage. Not only 
conditions that cause heart cell damage 
cause elevated troponin levels in the blood. 
Recent studies have shown that the kidneys 
are the major organs that eliminate tro-
ponin from the blood1. This statement is 
also confirmed by the fact that in end stage 
renal disease (ESRD) patients, especially 
in patients on hemodialysis, had elevated 
concentration of troponin in blood.2 High 
sensitive troponin T (hsTnT) and high sen-
sitive troponin I (hsTnI) are used today as 
specific cardiac damage markers. The in-
crease of their concentration above cut-off 
level indicates that cardiac events are most 
commonly reported. hs-TnT test has a de-
tection limit of 5 ng / L (pg / mL), while 
the quantification limit (LoQ) is 13 ng / L 
on the analytical system applied 3,4. hsTnI 
can be detected by Chemiluminescent Mi-
croparticle Immuno Assay (CMIA) meth-
od5. TnT blood levels in anuric patients on 
hemodialysis was increased in more than 
90% of patients, and the levels of TnI in 2/3 
of them6. Therefore, the diagnosis of acute 
cardiac event in these patients should in-
clude dominantly clinical symptoms and 
oscillations of troponin in time. Recent 
studies have shown that TnT and TnI con-
centrations in blood have prognostic value. 
Studies have shown that overall dialysis 
duration is not the main risk factor for 
mortality and that Tn has shown good cor-
relation with mortality risk. TnT is a good 
indicator of all-cause mortality, but TnI is 
proven to be in strong prognostic correla-
tion only with cardiac incidents7-9.  
Hemodialysis (HD) is one of the three 
replacement renal therapies. HD is usu-
ally performed three times a week for four 
hours. In case of instability of the patient, 
other replacement renal therapies are per-
formed with the aim of preventing the 
development of complications and im-
proving survival rate and quality of life.10 
According to the study, during HD, myo-
cardial perfusion decreases up to 44%.11 
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The decrease in perfusion causes changes 
in contractility of certain myocardial seg-
ments, and in about 30% of patients on 
HD, the ultrasound imaging of the heart 
can detect such changes. 12 These patients 
are at increased risk of development of sys-
tolic or diastolic heart failure. In addition, 
HD stimulates the inflammatory response 
of the body, and the inflammation enhanc-
es atherosclerotic changes in the blood 
vessels. Accelerated atherosclerosis leads 
to premature atherosclerosis of coronary 
blood vessels inducing hypoperfusion of 
the myocardium. In addition to the above-
mentioned, the frequency of systolic heart 
failure in the first year in patients on HD is 
about 40%, while the overall incidence of 
diastolic heart failure in patients on HD is 
25-87%, depending on the literature. 13-16
Since hsTn concentrations in blood are 
prognostic factors in patients on hemodi-
alysis, we wanted to examine how the he-
modialysis affects the elimination of TnT 
and TnI, and are TnT i TnI even excreted 
in dialysate. TnT is a molecule of about 40 
kDa in size and is predominantly degraded 
in blood on a 20 kDa immunoreactive seg-
ments. TnI is about 20 kDa in size and is 
also degraded in blood on smaller immu-
noreactive segments, dominantly 5-10 kDa 
in size.17 As the HD dominantly removes 
molecules of up to 10 kDa18 we have as-
sumed that TnI will be dominantly re-
moved from the blood in dialysate and that 
its dialysate concentrations will be greater 
than TnT concentrations.
The primary objective of this study was to 
determine the possibility of detection of 
TnT and TnI in dialysate using high-sen-
sitive tests (hsTnT, hsTnI). The secondary 
goal was quantification and comparison of 
TnT and TnI in dialysate samples of anu-
ric patients. We also wanted to examine 
whether the value of Tn concentration in 
dialysate measured 30 minutes before end 
of HD would be representative of the Tn 
concentration measured throughout dialy-
sis.
PATIENTS AND METHODS
The study included 5 anuric patients at-
tending HD procedure at KB Merkur on 
a regular basis. Patients were median age 
70 years old (MIN 58y, MAX 74y), with-
out heart failure and acute coronary dis-
ease. Three patients involved in the study 
had diabetes. The HD procedure was per-
formed in all patients three times a week 
for 4h, the ultrafiltration volume of di-
alysate was 2.2 ± 0.9 liters, depending on 
the required volume for removal.
The first sample of dialysate was taken af-
ter thirty minutes, the second sample was 
taken in the middle of dialysis (120th min-
ute) and the third sample was taken thirty 
minutes before the end of dialysis. We per-
formed dialysate sampling in the amount 
of up to 5 ml in each patient three times 
during one HD procedure to establish if 
there were differences between the meas-
ured concentrations in the different parts 
of the HD procedure.
The samples were stored at -80C until anal-
ysis. Dialysate used in HD procedure con-
tains sodium (139 mmol / L), chloride (108 
mmol / L), potassium (1.5 mmol / L), mag-
nesium (0.5 mmol / L), calcium (1.5 mmol 
/ L), acetate mmol / L), bicarbonate (34 
mmol / L) and glucose (1.0 g / L). Dialysate 
flow rates were 500 ml / min in all patients, 
respectively. Two patients included in the 
study were connected to the Rexed dialysis 
membrane while the other three were us-
ing the Frenius FX10.
hsTnI in dyalisate was determined by 
Chemiluminescent Microparticle Immuno 
Assay (CMIA) method, on an immuno-
chemical analyzer Abbott Architect i1000SR 
using 3P25 ARCHITECT STAT High Sens-
ititveTroponin-I Reagent Kit, 3P25 ARCHI-
TECT STAT High SensititveTroponin-I 
Calibrators and 3P25 ARCHITECT STAT 
High SensititveTroponin-I Controls19. The 
calibrators were prepared gravimetrically 
using recombinant human cardiac troponin 
IC complex and calibrator B was traced to 
NIST SRM 2921 at a concentration of 20 ng 
/ L 5. The value of hsTnT in dialysate was 
determined by immunochemical method 
with electrochemiluminescent detection on 
Roche cobas® e411 using Roche Diagnostics 
Troponin T high sensitive (TnT-hs) test, 
Roche Diagnostics PreciControl Troponin 
T as control, and Roche Diagnostics Tro-
ponin T hs CalSet calibrators3. The detec-
tion limit (LoD) by the reagent manufactur-
er (Roche Diagnostics) is 5 ng / L (pg / mL) 
and the limit of quantification (LoQ) 13 ng 
/ L on the applied analytical system 4. Veri-
fication of the manufacturer's LoQ value 
hsTnT is determined by CLSI EP17-A pro-
tocol. The same protocol was also applied 
to determine the limit of quantification of 
hsTnT in dialysate. Verification of hsTnT 
chemiluminescent micro-particle immuno-
assay on the analytical platform Roche co-
bas e411 was performed according to CLSI 
EP15-A2 protocol20. Limit of quantitation 
(LoQ) was determined according to CLSI 
EP17-A protocol. 
The statistical analysis was made using sta-
tistical program Statistics (version 13.1). 
Descriptive data analysis was performed for 
all attributes.
RESULTS
There were altogether 15 samples (three 
for each patient). The hsTnT level was de-
tectable in all 15 samples (13.42 ± 1.18 ng 
/ L), while hsTnI was only detectable in 8 
samples (0.14 ± 0.16 ng / L). The results are 
shown in Table 1. To test the difference in 
detectability between hsTnT and hsTnI, chi 
square test was used and the difference was 
statistically significant (Yates chi-square 
6.708, p = 0.009). To test the difference 
between total TnT and TnI concentrations 
in dialysate, Student s T test for dependent 
samples was used, which showed that the 
difference was statistically significant (t = 
44.9028, p <0.001).
The mean difference of TnT level in di-
alysate 30 minutes before the end of dialy-
sis (13.27 ± 0.74ng/L) did not shown statis-
tically significant compared to the average 
TnT concentration measured in dialysate 
of all samples (13.42 ± 1.1 ng /L) (for the 
analysis we used Wilcoxon W test, p-value: 
0.9530). The difference between TnI in di-
alysate 30 minutes before dialysis endpoint 
(0.16 ± 0.23 ng / L) was not statistically 
significant compared to the mean TnI con-
centration in dialysate of all samples (0.14 
± 0.16 ng / L) (fot the analysis we used Wil-
coxon W test, p-value: 1.0000). 
                    
DISCUSSION
This research has for the first time shown 
that TnT and TnI are removed by dialysis 
in anuric patients on HD. Dialysate is an 
isotonic fluid with normal blood osmolar-
ity and serves to allow the removal of ex-
cess metabolic waste substances from a pa-
tient's body. Dialysate flow, used in HD, is 
usually 500 ml/min, which was the case in 
this study, but may range from 350 to 600 
ml / min10. Its flow determines the total 
amount of dialysate to be used in dialysis, 
so the most commonly used dialysate vol-
ume is around 120 L. 
In accordance with our previous research, 
we have proved that it is possible to meas-
ure hsTn in urine, and this research con-
firmed the possibility of measuring hsTn 
in dialysate1. We have confirmed that a 
measurement finding is not random be-
cause we measured the hsTn concentration 
on several occasions during HD. Another 
reason why we measured Tn concentra-
tions three times during dialysis was that 
we were unable to store the entire dialysate 
(around 120L) in laboratory conditions to 
determine the troponin values in the over-
all dialysate. Dialysate samples were taken 
from each patient three times during one 
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HD procedure, which have proven the dif-
ferences between the measured concentra-
tions of TnT and TnI in dialysate. hsTnT 
was present in all dialysate samples and 
its concentration was stable in dialysate. 
hsTnI concentrations were detectable in 
significantly lower concentrations. The lit-
erature states that TnI binds to the dialysis 
membrane21. This claim has so far been 
confirmed only in in vitro conditions. Our 
research confirmed this claim, but in vivo 
conditions.
One of the potential limitations of this 
study is that hsTnT and hsTnI assays are 
not standardized for dialysate. Since the 
manufacturers claim that it is possible to 
use the mentioned tests in all body flu-
ids, and that dialysate is a fluid similar to 
plasma, there is no reason not to apply 
these tests for dialysate19-20. So, there is 
no reason, for the Tn concentrations meas-
ured in dialysate, to be invalid. The results 
obtained confirm that the results could be 
valid because, as expected, the TnI values 
were significantly lower than the TnT con-
centration due to the TnI binding to the 
dialysis membrane22.   
CONCLUSION
The presence of Tn molecules in dialysate 
was determined for the first time. TnT val-
ues in dialysate were much higher than the 
TnI values that were barely measurable. 
These TnI concentrations are consistent 
with the expected values since TnI has 
been shown to bind to the dialysis mem-
brane.
Since differences in Tn concentration be-
tween the measured values were not statis-
tically significant, we can safely claim that 
one-time measurement of troponin (either 
TnT or TnI) in dialysate during dialysis 
represents the representative Tn value in 
dialysate.
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